excretion. In rats also, zonampanel is predominantly eliminated via urine but partly also via bile as the unchanged form. In this study, the molecular mechanism of the excretion of zonampanel was elucidated using cells expressing rat Oat1, Oat2, and Oat3. Furthermore, zonampanel (15 mg/kg) was given intravenously to rats with or without probenecid (50 mg/kg) or cimetidine ( suggest that, in rats, zonampanel is taken up from the blood into proximal tubular cells via Oat1 and Oat3 and, unlike the case in humans, also into hepatocytes via Oat2 and Oat3. The inter-species differences in the excretion of zonampanel between rats and humans may thus be explained by those in the substrate selectivity and tissue distribution of OATs.
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Introduction
Zonampanel monohydrate (YM872), [2,3-dioxo-7 -(1H-imidazol-1-yl)-6-nitro-1,2,3,4-tetrahydro-1-quinoxalinyl] acetic acid monohydrate (Fig. 1) , is a selective antagonist of the glutamate receptor subtype, α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor and has been expected as a drug for the treatment of cerebral vascular disorders such as cerebral ischemia. Intravenous infusion of zonampanel has been shown to reduce the volume of ischemic damage in rats (Kawasaki-Yatsugi et al., 1998) and cats (Takahashi et al., 1998) .
The major elimination route of zonampanel is renal excretion in humans (Minematsu et al., 2005) . Potential mechanisms by which intravenously administered zonampanel is excreted unchanged into the urine in humans have been identified. The high renal clearance of this drug, about 30-fold greater than the product of the glomerular filtration rate (GFR), and the unbound fraction in plasma (f p ) suggests that renal tubular secretion contributes to excretion in the urine (Minematsu et al., 2005) . Moreover, zonampanel, which exists as an anion under physiological conditions (pH around 7.0 to 7.4), is transported by human organic anion transporter 1 (OAT1) and OAT3, but not by OAT2 (Hashimoto et al., 2004) . A recent review article described the expression of transporters in the human proximal renal tubule, including OAT1 and OAT3 on the basolateral membrane (Shitara et al., 2005) . Human OAT1 and OAT3 on the basolateral membrane transport zonampanel from the blood into renal proximal tubular cells. Renal tubular secretion is accomplished by membrane transport in two steps: 1. uptake from blood through the basolateral membrane to the proximal tubular cells; and 2. excretion from cells to the tubular lumen DMD#19828 10 Oat2 and Oat3 were subcloned into mammalian expression vector pcDNA3.1/zeo(+) (Invitrogen, Carlsbad, CA) . The vector constructs of rat Oat1 and Oat3, as well as the empty vector were introduced into parental HEK293 cells (rat Oat1-HEK293, rat Oat3-HEK293, and mock-HEK293, respectively) with Lipofectamine 2000 (Invitrogen) transfection reagent according to the manufacturer's protocol. Stably transfected cells were selected by adding zeocin (Invitrogen) to the culture medium. Rat Oat1-HEK293, rat Oat3-HEK293, and mock-HEK293 were grown in Dulbecco's modified Eagle's medium (Invitrogen) supplemented with 10% heat-inactivated fetal bovine serum, 50 U/ml penicillin, 50 µ g/ml streptomycin, and 100 µ g/ml zeocin at 37 °C with 5%
CO 2 under humidified conditions on the bottom of a dish. When the vector construct of rat Oat2 was introduced into parental HEK293 cells, no rat Oat2 function (the uptake of [ 3 H]salicylic acid) was observed. Therefore, the vector construct of rat Oat2 and the empty vector were subsequently introduced into parental LLC-PK1 cells (rat Oat2-LLC-PK1 and mock-LLC-PK1, respectively) with Lipofectamine 2000 transfection reagent. Stably transfected cells were selected by adding zeocin to the culture medium. Rat Oat2-LLC-PK1 and mock-LLC-PK1 were grown in medium 199 (Invitrogen) supplemented with 10% heat-inactivated fetal bovine serum and 100 µ g/ml zeocin at 37 °C with 5% CO 2 under humidified conditions on the bottom of a dish. The cells were seeded in poly-D-lysine-coated 12-well plates (BD Biosciences, Franklin Lakes, NJ) at a density of 2.0 × 10 5 cells/well. Cell culture medium was replaced with culture medium supplemented with approximately 5 mM sodium butyrate one day before transport studies to induce the expression of proteins.
This article has not been copyedited and formatted. The final version may differ from this version. Hionic-Fluor (Perkin-Elmer) was added. Radioactivity was measured using liquid scintillation counters Tricarb-2900 and -3100 (Perkin-Elmer). Aliquots (40 µ l) were used to determine protein concentrations by the method of Lowry using a DC protein assay kit (Biorad Laboratories, Hercules, CA) with bovine serum albumin as a standard.
Transport Studies Using Rat Oatp1, Oatp2 and Oatp4-expressing Oocytes.
Upon receipt, purchased oocytes were kept at 16°C until use in the transport studies on the same day. The uptake experiment was performed at room temperature and initiated by pipetting oocytes into 2 ml of Na + buffer containing a radiolabeled ligand at a designated concentration after oocytes had been washed with the buffer . The Na + buffer consisted of 100 mM NaCl, 2 mM KCl, DMD#19828 12 1 mM MgCl 2 , 1 mM CaCl 2 , and 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (pH 7.4). Uptake was terminated at the designated time by pipetting the oocytes into ice-cold Na + buffer (2 ml). Oocytes were then washed by transferring the oocytes into 2 ml of fresh ice-cold Na + buffer (repeated 3 times). To determine the uptake of radiolabeled ligands, each oocyte was transferred to a scintillation vial and dissolved using 10%(w/v) sodium dodecyl sulfate solution.
For water-injected and transporter-expressing oocytes, 10 and 15 oocytes, respectively, were used.
For the uptake of [ 14 C]zonampanel, five of oocytes were pooled to obtain a radioactivity level above the lower limit of detection (consequently two and three samples of pooled oocytes for water-injected and transporter-expressing oocytes, respectively, were prepared). Subsequently, Hionic-Fluor scintillation cocktail was added to vials, and the radioactivity was measured using liquid scintillation counters Tricarb-3100. 
Vesicular Transport Assays Using
In Vivo Study in Rats.
Seven-week-old male Sprague-Dawley rats were purchased from Japan SLC (Hamamatsu, Japan) and used at eight weeks after acclimatization for at least one week. During acclimatization, the rats were kept in an air-conditioned room with temperature and humidity controlled at 22.9 to 23.3 °C and 50% to 78%, and lit for 12 h 30 min from 7:30 to 20:00. They were given free access to solid food (CE-2; CLEA Japan Inc; Tokyo, Japan) and water until just before drug administration. This animal experiment was approved by the Animal Care Committee of Astellas Pharma Inc. Zonampanel (15 mg/kg) was administered at a single bolus dose into the rat tail vein with or without probenecid (50 mg/kg) or cimetidine (40 mg/kg). At 5, 15, and 30 min, and 1, 2, 3, 4, and 6 h after dosing, blood was sampled under ether anesthesia via the inferior vena cava using a heparinized syringe and immediately stored on ice using 4 rats each per sampling time point per administration group (total 128 rats for 8 sampling time points and 4 administration groups). Plasma was obtained by centrifugation at 4 °C, 1,870 × g for 15 min and kept frozen at −20 °C until assay as described below. Rats for plasma sampling at 3 and 6 h after administration were housed in metabolic cages after administration, and spontaneously excreted urine was collected and the cages were washed using water. Regarding specific gravity as 1, urine volume (including the cage-wash water) was calculated according to differences in the weight of the sampling tube before and after sampling. Urine samples were kept frozen at −20 °C until assay as described below. All plasma and urine samples were protected from light throughout the sampling, storage and assay procedures.
Analytical Methods.
Determination of plasma zonampanel concentrations was conducted using a validated high performance liquid chromatography assay with ultraviolet detection (HPLC-UV) (Noguchi et al., 2008) . Briefly, 0.1 ml portions of internal standard solution (10 µg/ml YM-53362 solution in 0.01 M HCl) were added to 1 ml of plasma, followed by the addition of 0.1 M tris-HCl buffer (pH 7). The mixture was vortexed for about 5 s and centrifuged at 830 × g for 5 min at 4 °C, and the supernatant was applied to a Sep-Pak cartridge (Waters, Milford, MA) preconditioned using methanol and water. After the cartridge was washed twice using 2.5 ml each of 0.1 M tris-HCl buffer (pH 7), zonampanel and internal standard were eluted using 75% methanol. After addition of 0.1 ml of 0.5 M HCl, the eluate was vortexed for about 5 sec. Then, after addition of 6 ml of tri-n-butyl phosphate with 5% water, the sample was shaken for 10 min (200 stroke/min) and centrifuged at 830×g for 5 min at 4°C, and the organic phase was aspirated off (performed twice.
An aliquot (0.1 ml) of aqueous phase was injected into the HPLC system. Chromatographic v/v/v), pumped at a rate of 1.0 ml/min. The detection absorbance was set at 333 nm, and calibration ranged from 10 to 5000 ng/ml. Accuracy and precision at concentrations including the lower limit of quantification (LLOQ) were 0.78% to 5.36% and 0.70% to 4.51%, respectively.
When the concentration of a sample was expected to exceed the upper limit of quantification, the sample was diluted using blank plasma. For the calculation of means and standard deviations, measured concentrations below the LLOQ (10 ng/ml) were regarded as 0.00 ng/ml.
Determination of urinary zonampanel concentrations was conducted using a validated HPLC-UV method, which was modified from the method for plasma. Briefly, 0.1-ml portions of internal standard solution (10 µg/ml YM-53362 solution in 0.01 M HCl) were added to 0.2 ml of the urine sample diluted 100-fold with water. After mixing, 0.1 ml of aqueous phase was injected into the HPLC system under the same conditions as above. Calibration ranged from 10 to 5000 µg/ml. Accuracy and precision at concentrations including the LLOQ were -2.37% to -1.00% and 0.62% to 2.36%, respectively. Cumulative urinary excretion ratio of zonampanel (A e , % of dose) was calculated using dose, urine volume and urinary concentration.
Pharmacokinetic Analysis.
Time profiles of the mean plasma concentration of zonampanel were applied to a non-compartmental model (linear trapezoidal method) using the WinNonlin program and the This article has not been copyedited and formatted. The final version may differ from this version. (3) to (8) Hypothesis for renal clearance 1. It was hypothesized that resorption is negligible since CL renal,b is much larger than (f p /R b ) ⋅ GFR.
2. It has been reported that the parallel tube model is more suitable for the description of renal tubular secretion than the well-stirred model (Janku, 1993; Janku and Zvara, 1993) . It was thus hypothesized that CL renal,sr,b can be described according to the parallel tube model using the following equation (1):
where R b is blood-to-plasma concentration ratio and Q renal is renal blood flow.
Hypothesis for biliary excretion clearance
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where Q hepatic is hepatic blood flow.
Equations for parameters
Equation (1) gives
Equation (2) gives
where A e0→6h is urinary excretion of zonampanel from 0 to 6 h after dosing.
Values of R b , f p , GFR, Q renal , and Q hepatic were fixed at 0.64 for R b (unpublished data), 0.125 for f p (unpublished data), 11.4 ml/min/kg for GFR (Fischer et al., 2000) , 40.71 ml/min/kg for Q renal (Delp et al., 1991) , and 55.2 ml/min/kg for Q hepatic (Davies and Morris, 1993) reported that probenecid does not affect GFR in rats (Darling and Morris, 1991; Foote and Halstenson, 1998) , while another noted that, given that it has no effect on blood flow in the renal vein in dogs (Barza et al., 1975) , probenecid is unlikely to change renal blood flow in rats.
Cimetidine did not affect GFR or renal blood flow rate in rats (Foote and Halstenson, 1998; Rothwell NJ et al., 1984) . The change in the CL bile,int,all should be carefully considered (the decrease in CL bile,int,all may be underestimated), given probenecid increases blood flow in the portal vein of dogs (Barza et al., 1975) .
This article has not been copyedited and formatted. The final version may differ from this version. ± 69, and 0.920 ± 0.053 µ M, respectively, and those of cimetidine were >1000, >1000, and 33.7 ± 12.8 µ M, respectively (estimate ± standard error). In this study, about 25% of the rat Oat2-mediated uptake activity for [ 14 C]salicylic acid remained in the presence of 1 mM probenecid, which was comparable with the results of the previous study (Morita et al., 2001) . Values for the kinetic parameters K m and K i were comparable with those in the literature (Burckhardt and Burckhardt, 2003) . Therefore, functional verification of cells stably expressing rat Oat1, Oat2, and Oat3 using their prototypical substrates and inhibitors was successfully performed.
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Inhibitory Effects of Probenecid and Cimetidine on Rat Oat1, Oat2 and Oat3-mediated
Uptake of Zonampanel.
Probenecid inhibited rat Oat1-and Oat3-mediated uptake of [ 14 C]zonampanel, but had only a weak inhibitory effect on rat Oat2-mediated uptake (Fig. 4, Table 3 ). In contrast to the results for rat 
Discussion
Although zonampanel is metabolized only slightly in both rats and humans (Sohda et al., 2004; Minematsu et al., 2005) , fecal excretion of [ 14 C]zonampanel is much greater in rats (30% of dose, unpublished data) than in humans (0.5% of dose) (Minematsu et al., 2005) . Here, we investigated the molecular mechanisms of zonampanel excretion in rats and the reason for the inter-species differences in excretion between rats and humans using cell lines stably expressing rat Oat1, Oat2, and Oat3. In addition, we also tested the effects of the organic anion transporter inhibitors probenecid and cimetidine on the pharmacokinetics of zonampanel in rats. Species-differences in the substrate selectivity and distribution/localization of OATs well explained the difference in the excretion.
Zonampanel is a substrate of rat Oat1, Oat2, and Oat3 (Fig. 3) , and human OAT1 and OAT3, but is not transported by human OAT2 (Hashimoto et al., 2004) . Expression levels of OAT1 mRNA in the liver are much lower than those in the kidney in both rats and humans (Race et al., 1999; Buist et al., 2002) . In both species, OAT2 is expressed on the basolatelaral membranes of the hepatocytes (Shitara et al., 2005) . In contrast, although the mRNA of OAT3 is expressed in rat liver (Kusuhara et al., 1999; Buist et al., 2002) , it is not detected in human liver (Race et al., 1999) . In rats, OAT2 and OAT3 may accelerate the uptake of zonampanel from the blood into the liver, resulting in greater fecal excretion via bile than in humans. Regarding renal excretion, a recent review article described the expression of OAT1 and OAT3 on the basolateral membrane of rat and human proximal renal tubule (Shitara et al., 2005) . It is therefore likely that zonampanel is This article has not been copyedited and formatted. The final version may differ from this version. rapidly secreted from blood into the urine via OAT1 and OAT3 in both rats and humans. OAT2 is localized in different regions of the kidney in rats and humans. For rats, it is found on the apical membrane of the tubules in the medullary thick ascending limb of Henle's loop and collecting ducts for rats; while for humans, it is found on the basolateral membrane of the tubule for humans (Kojima et al., 2002; Shitara et al., 2005) . Therefore, rat Oat2 may mediate zonampanel reabsorption rather than its secretion into the urine.
In this study, after intravenous administration of zonampanel (15 mg/kg) without probenecid or cimetidine to rats, plasma concentration of zonampanel was about 30 µg/ml (86 µM) at the first sampling time (5 min), which rapidly decreased to around 0.1 µg/ml within 120 min. Because the unbound fraction of zonampanel in rat plasma was 0.125, when total plasma concentration of zonampanel is 30 µg/ml, the unbound plasma concentration is 11 µM, which is lower than the K m values of zonampanel for rat Oat1, Oat2, and Oat3. Similar plasma concentrations were obtained in a preliminary study (unpublished results). In a clinical study, using intravenous constant infusion, the plasma concentration of zonampanel reached 2.93 µg/ml (8.4 µM; 0.84 µM as unbound) as previously reported in our report (Minematsu et al., 2005) . Intravenous bolus adminsitration of zonampanel 15 mg/kg to rats can result in this concentration. Therefore, the dose of zonampanel was chosen as 15 mg/kg. While C 0 ranged from 57.8-102 µg/ml (165-291 µM) ( within 6 h in rats (Table 4 ). In addition, renal clearance of zonampanel was higher than the product of f p and GFR, indicating that tubular secretion plays an important role in the renal excretion of this drug. In combination with probenecid, renal clearance and intrinsic renal secretion clearance decreased to 33.8% and 17.4%, respectively, compared with the control group (Table 4) , suggesting a transporter inhibition-induced decrease in tubular secretion.
Non-renal and intrinsic non-renal clearance of zonampanel in the probenecid-coadministered group also decreased to 36.9% and 32.9%, respectively, of that in the control (Table 4) .
Probenecid has been reported to inhibit the transporter-mediated biliary excretion of NBQX, 6-nitro-7-sulfamoyl-benzo(f)quinoxaline-2,3-dione, which has a similar chemical structure to zonampanel, in rats (Hansen, 1995) . On this basis, probenecid was considered to inhibit transporter-mediated biliary excretion (in this case the uptake into the hepatocytes) of zonampanel.
In a rat study, radioactivity after intravenous administration of [ 14 C]zonampanel was mainly distributed in the kidney and liver (unpublished data). The reduced V ss (Table 4) agrees with decreased cellular uptake due to the inhibition of transporters by probenecid in the basolateral membrane of the proximal renal tubule and of hepatocytes. When probenecid was given to rats at 50 mg/kg, unbound plasma concentrations were approximately 100 µg/ml (350 µM) at 2.5 min, > 10 µg/ml (35 µM) at 1 h and > 2 µg/ml (7 µM) at 2 h after dosing (Emanuelsson and Paalzow, 1988 probenecid inhibited Oat2 in the in vivo experiments. The lack of complete inhibition of the renal and non-renal clearance of zonampanel could also be due to lack of Oat2 inhibition, slight saturation for kinetics just after administration as described above, and/or involvement of the other transporters.
Similar to the case with probenecid, the renal and intrinsic renal secretion clearance of zonampanel in the cimetidine-coadministered group was decreased to 64.9% and 49.6%, respectively, of that in the control group (Table 4) , suggesting the inhibition of Oat3. The non-renal and intrinsic non-renal clearance of zonampanel in the cimetidine-coadministered group was also decreased to 57.2% and 53.5%, respectively, of that in the control group (Table 4) , also suggesting the inhibition of Oat3. Further, the V ss of zonampanel also decreased in the cimetidine-coadministered group (Table 4) . When cimetidine was given to rats at 40 mg/kg, the plasma cimetidine concentration was approximately 20 µg/ml (80 µM) at about 5-10 min, 10 µg/ml (40 µM) at 0.5 h, > 3 µg/ml (12 µM) at 1 h and > 1 µg/ml (4.0 µM) at 2 h after administration, and f p was 0.78 to 0.83 (5 to 50 µg/ml) in rats (Adedoyin et al., 1987) , suggesting an unbound plasma cimetidine concentration of approximately 64 µM at about 5-10 min, 32 µM at 0.5 h, > 9. of zonampanel, this may be due to lack of Oat1/Oat2 inhibition, slight saturation for kinetics just after administration as described above, and/or involvement of the other transporters.
In rats, organic anion transporters other than Oats, such as oatp1, oatp2 and oatp4 are localized on the basolateral membrane of hepatocytes: oatp1 is on the apical membrane of the renal tubules, and Mrp2 is on the apical membranes of the hepatocytes and renal tubules (Shitara et al., 2005) . The importance of these transporters in the pharmacokinetics of zonampanel may be low, but oatp4 might be partly involved in the uptake of zonampanel into hepatocytes ( Fig. 5 ; any statistical significance in the difference between the uptake into water-injected and oatp4-expressing oocytes could not be tested). A future detailed study may reveal the involvement of oatp4 in more quantitative manner. Because zonampanel is not a good substrate of rat Mrp2, we could not find the transporters involved in the secretion across the apical membrane of hepatocytes and renal tubules. For the accumulation of zonampanel in the liver and kidney, the tissue-to-plasma radioacivity concentration ratio was about 1.6 for the liver and 7 for the kidney after the intravenous administration of [ 14 C]zonampanel to rats (unpublished data; radioactivity represents the unchanged zonampanl, because zonampanel is metabolized only slightly as described above). Therefore, the uptake process on the basolateral membrane is likely dominant to the efflux process on the apical membrane.
In conclusion, zonampanel was transported by rat Oat1, Oat2, and Oat3 in a 
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